US68235C2061 - Common Stock
ONCOCYTE CORP
NASDAQ:OCX (9/6/2024, 8:00:02 PM)
After market: 2.89 -0.3 (-9.4%)3.19
+0.14 (+4.59%)
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 43 full-time employees. The company went IPO on 2015-12-30. The firm is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.
ONCOCYTE CORP
15 Cushing
Irvine CALIFORNIA 92618
P: 19494097600
CEO: Ronald Andrews
Employees: 43
Website: https://oncocyte.com/
Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study...
OCX stock results show that OncoCyte beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips OncoCyte (NASDAQ:OCX) just reported results for the second quarter of 2024.Onco...
Oncocyte Announces Successful GraftAssureTM Beta Launch and Q2 2024 Results...
Oncocyte Announces August Investor Conferences Participation...
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8...
Here you can normally see the latest stock twits on OCX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: